$20.02
-0.67-3.24%
Last update: Nov 5, 7:51 PM
Replimune Group Inc (REPL) Stock Price, Quote, News & History
REPLNASDAQ
FDA grants Replimune accelerated approval for TUDRIQEV in combination with nivolumab to treat advanced cutaneous melanoma.
You can purchase shares of Replimune Group (NASDAQ:REPL) through any online brokerage.
Other companies in Replimune Group’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Replimune Group has a consensus price target of $15.00.
The stock price for Replimune Group (NASDAQ: REPL) is $20.05 last updated November 5, 2026 at 7:51 PM EST.
There are no upcoming dividends for Replimune Group.
Replimune Group does not have any upcoming earnings scheduled.
There is no upcoming split for Replimune Group.
Replimune Group is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic...
